Adaptive Biotechnologies
Adaptive Biotechnologies' revenue rose 54.8% to $277 million in fiscal 2025. Its operating margin was −20.6%, up from −90.8% a year earlier. Free cash flow was −$49 million. The diluted share count rose 3.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Adaptive Biotechnologies does
Adaptive Biotechnologies reads the genetic code of a patient's immune system to find out how the body detects and fights disease. It uses gene-sequencing technology, a growing database and machine learning to build diagnostic tests and drug-discovery tools.
It has two main businesses. The first, minimal residual disease (MRD) testing, uses its clonoSEQ test to find tiny amounts of cancer left in patients with blood cancers. clonoSEQ is sold to doctors as a clinical test and to drug companies as an assay for their clinical trials (called MRD Pharma). Adaptive says it was the first test authorized by the U.S. Food and Drug Administration to detect and monitor MRD in multiple myeloma, B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
The second, Immune Medicine, uses its ability to sequence and map immune cell receptors at scale to support new diagnostic and drug products. Adaptive reorganized the company around these two businesses in 2024.
Its biggest risks, as it describes them
- It has lost money since it began and may not reach or keep profitability.
- Insurers and government programs may not cover or pay enough for its clinical tests.
- It may not be able to expand clonoSEQ to new uses or turn its immune platform into new products.
- It relies on a limited number of suppliers, often a single one, for lab equipment and materials.
- Its research spending on new products and services may not pay off.
Income statement
Adaptive Biotechnologies lost money in fiscal 2025: a net loss of $60 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 353 | 498 | 346 | 222 | 227 |
| Debt incl. finance leases | — | 125 | 131 | 133 | 131 |
| Net debt (negative means net cash) | — | −373 | −216 | −89 | −96 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.3x | 0.4x | 0.7x | 0.6x |
| Interest coverage | — | −47.2x | −16.4x | −14.0x | −4.8x |
| Current ratio | 3.5x | 5.1x | 4.7x | 2.9x | 3.3x |
| Quick ratio | 3.4x | 5.0x | 4.5x | 2.8x | 3.2x |
Cash flow
Projections
Project Adaptive Biotechnologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Adaptive Biotechnologies says to expect
- Full year 2026: MRD revenue
Adaptive Biotechnologies expects full year revenue for the MRD business to be between $276 million and $286 million, updated from the previous range between $268 million and $278 million.
- Full year 2026: operating expenses
We expect full year total company operating expenses, including cost of revenue, to be approximately $350 million, updated from the previous range between $350 million and $355 million.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Adaptive Biotechnologies shares on the open market, and 11 insiders sold $121.6 million, $87.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Julie RubinsteinPresident and COO | Sold plan | 11,466 | $28.93 | $331,711 | Form 4 |
| Nov 12, 2026 | Julie RubinsteinPresident and COO | Sold plan | 11,881 | $29.40 | $349,301 | Form 4 |
| Nov 11, 2026 | Julie RubinsteinPresident and COO | Sold plan | 11,881 | $30.83 | $366,291 | Form 4 |
| Nov 11, 2026 | Susan BobulskyChief Commercial Officer, Mrd | Sold plan | 1,875 | $32.00 | $60,000 | Form 4 |
| Sep 16, 2026 | Francis LoChief People Officer | Sold plan | 115,406 | $28.06 | $3.2 million | Form 4 |
| Sep 15, 2026 | Susan BobulskyChief Commercial Officer, Mrd | Sold plan | 1,195 | $27.00 | $32,265 | Form 4 |
| Aug 26, 2026 | Katey Einterz OwenDirector | Sold | 9,615 | $26.00 | $249,990 | Form 4 |
| Aug 18, 2026 | Chad M RobinsCEO and Chairman, Director | Sold | 278,676 | $24.48 | $6.8 million | Form 4 |
| Aug 18, 2026 | Robert HershbergDirector | Sold | 30,664 | $24.40 | $748,208 | Form 4 |
| Aug 17, 2026 | Chad M RobinsCEO and Chairman, Director | Sold | 321,324 | $25.08 | $8.1 million | Form 4 |
| Aug 17, 2026 | Peter M NeupertDirector | Sold | 124,690 | $25.15 | $3.1 million | Form 4 |
| Aug 10, 2026 | Susan BobulskyChief Commercial Officer, Mrd | Sold plan | 3,000 | $25.00 | $75,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 9 | 4 of 9 | 5 of 9 |
| Rule of 40 | −106.2% | −50.1% | 37.1% |
| Altman Z'' | −3.84 | −7.02 | −5.91 |
| Accruals ratio | −9.1% | −10.7% | −2.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 1 of 9 | 4 of 9 | 5 of 9 |
Compare
Put Adaptive Biotechnologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies | FY25 | 54.8% | −20.6% | −17.7% | −37.2% | — | 5 | |
| Vericel | FY25 | 16.4% | 4.0% | 9.0% | — | — | — | Compare |
| Ligand Pharmaceuticals | FY25 | 60.4% | 15.3% | 18.2% | 4.9% | −3.8x | 5 | Compare |
| Iovance Biotherapeutics | FY25 | 60.6% | −153.1% | −127.6% | — | — | — | Compare |
| Arvinas | FY25 | −0.3% | −45.1% | −105.0% | — | — | 5 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 38 | 56 | 85 | 98 | 154 | 185 | 170 | 179 | 277 |
| Revenue growth | — | 44.8% | 52.8% | 15.7% | 56.9% | 20.1% | −8.1% | 5.1% | 54.8% |
| Gross profit | 23 | 36 | 63 | 76 | 105 | 127 | 95 | 107 | 206 |
| Research and development | 32 | 39 | 71 | 116 | 142 | 142 | 122 | 103 | 94 |
| Operating income | −44 | −50 | −78 | −153 | −209 | −200 | −227 | −162 | −57 |
| Net income | −43 | −46 | −69 | −146 | −207 | −200 | −225 | −160 | −60 |
| Diluted EPS (US$) | −3.50 | −3.67 | −1.01 | −1.11 | −1.48 | −1.40 | −1.56 | −1.08 | −0.39 |
| Diluted shares (millions) | 12 | 13 | 69 | 131 | 140 | 142 | 144 | 147 | 152 |
| Cash flow | |||||||||
| Cash from operations | −35 | −32 | 205 | −150 | −193 | −184 | −156 | −95 | −46 |
| Capital expenditure | 2 | 6 | 11 | 19 | 62 | 16 | 11 | 4 | 3 |
| Free cash flow | −37 | −39 | 194 | −168 | −254 | −200 | −167 | −99 | −49 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 11 | 13 | 25 | 43 | 56 | 63 | 54 | 52 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | — | 165 | 577 | 688 | 353 | 498 | 346 | 222 | 227 |
| Debt incl. finance leases | — | — | — | — | — | 125 | 131 | 133 | 131 |
| Total assets | — | 333 | 912 | 1,116 | 923 | 857 | 661 | 539 | 513 |
| Total liabilities | — | 30 | 341 | 373 | 319 | 392 | 353 | 337 | 288 |
| Shareholders' equity | −225 | −258 | 571 | 743 | 604 | 464 | 308 | 203 | 219 |
| Margins and ratios | |||||||||
| Gross margin | 59.2% | 64.7% | 73.8% | 77.1% | 68.1% | 68.8% | 55.6% | 59.7% | 74.2% |
| Operating margin | −115.7% | −89.4% | −92.2% | −155.3% | −135.4% | −108.0% | −133.3% | −90.8% | −20.6% |
| Net margin | −111.4% | −83.4% | −80.7% | −148.6% | −134.3% | −108.0% | −132.3% | −89.1% | −21.5% |
| Free cash flow margin | −97.0% | −69.3% | 228.3% | −171.3% | −164.9% | −108.1% | −98.1% | −55.2% | −17.7% |
| Rule of 40 (growth + FCF margin) | — | −24.5% | 281.1% | −155.6% | −108.0% | −88.0% | −106.2% | −50.1% | 37.1% |
| Return on capital | — | — | — | — | — | — | −195.2% | −124.7% | −37.2% |
| Return on equity | — | — | −43.9% | −22.2% | −30.8% | −37.5% | −58.3% | −62.4% | −28.2% |
| Return on assets | — | — | −11.0% | −14.4% | −20.3% | −22.5% | −29.7% | −26.6% | −11.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |